GSK turns to Chiome for antibody discovery

GlaxoSmithKline ($GSK) has turned to Japan's Chiome Bioscience to help hunt up new antibodies to fight cancer. GSK plans to start with a pilot program to test Chiome's antibody platform. Chiome, which boasts some fast turnaround times, has also inked deals with Five Prime Therapeutics and OncoMed Pharmaceuticals. No financial details were discussed. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.